Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: A prospective study in clinical practice

Journal of Rheumatology

Volumn 40, Issue 9, 2013, Pages 1479-1486

  Linde, Louise ^a   Sørensen, Jan ^a   Østergaard, Mikkel ^b   Hetland, Merete Lund ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

Biological therapy; Quality adjusted life years; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; IMMUNOGLOBULIN M; INFLIXIMAB; RHEUMATOID FACTOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COMORBIDITY; DANISH; DAS28; DEMOGRAPHY; DENMARK; DISEASE ASSOCIATION; DISEASE DURATION; ETHNICITY; EUROPEAN LEAGUE AGAINST RHEUMATISM; EUROPEAN QUALITY OF LIFE FIVE DIMENSIONS; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RATING SCALE; RHEUMATOID ARTHRITIS; SELF REPORT; SOCIAL STATUS; TREATMENT DURATION; TREATMENT RESPONSE;

BIOLOGICAL THERAPY; QUALITY-ADJUSTED LIFE-YEARS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; REGISTRIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84883319867     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121387     Document Type: Article

References (29)

1. van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 2006;65:328-34. (Pubitemid 43268221)
2. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65. (Pubitemid 38480815)
3. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
4. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
5. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46:1345-54. (Pubitemid 47244512)
6. Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care Res 2010;62:1399-406.
7. Lekander I, Borgstrom F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. Int J Technol Assess Health Care 2010;26:54-61.
8. Virkki L, Konttinen Y, Peltomaa R, Suontama K, Saario R, Immonen K, et al. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2008;26:1059-66.
9. Rupp I, Boshuizen HC, Dinant HJ, Jacobi CE, van den Bos GA. Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand J Rheumatol 2006;35:175-81. (Pubitemid 43890736)
10. Rupp I, Boshuizen HC, Roorda LD, Dinant HJ, Jacobi CE, van den Bos G. Poor and good health outcomes in rheumatoid arthritis: the role of comorbidity. J Rheumatol 2006;33:1488-95. (Pubitemid 44168817)
11. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Rasmussen C, Jensen DV, et al. What factors influence the health status of patients with rheumatoid arthritis measured by the SF-12v2 Health Survey and the Health Assessment Questionnaire? J Rheumatol 2009;36:2183-9.
12. Chorus AM, Miedema HS, Boonen A, Van Der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003;62:1178-84. (Pubitemid 37500623)
13. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010;37:285-90.
14. Hetland ML. DANBIO: A nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005;23 Suppl 39:S205-7. (Pubitemid 46657530)
15. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health 2009;37:459-66.
16. Kind P. A five-level version of EQ-5D. Value Health 2004;7:637-57.
17. Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007;45:259-63.
18. Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health 2008;11:275-84. (Pubitemid 351473607)
19. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36.
20. Janssen MF, Birnie E, Bonsel GJ. Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Qual Life Res 2008;17:463-73.
21. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15.
22. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82. (Pubitemid 40126441)
23. Allard S, NAME IT Study Group. Phase IIIB.IV clinical study report of a double-blind, randomised, controlled study to compare methotrexate plus Neoral® versus methotrexate plus placebo in subjects with early severe rheumatoid arthritis. Basel, Switzerland: Novartis Pharma; 2000.
24. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523-32. (Pubitemid 40848233)
25. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50:196-203.
26. Molenaar ET, Voskuyl AE, Dijkmans BA. Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol 2002;29:267-70. (Pubitemid 34118771)
27. Plant MJ, O'Sullivan MM, Lewis PA, Camilleri JP, Coles EC, Jessop JD. What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time? Rheumatology 2005;44:1181-5. (Pubitemid 41236028)
28. Kobelt G, Lindgren P, Geborek P. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. Scand J Rheumatol 2009;38:409-18.
29. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. Int J Technol Assess Health Care 2009;25:181-9.